Article Sidebar

PDF
Date Published: 21/07/2021
Abstract Views: 229
Views PDF: 212
DOI: https://doi.org/10.51298/vmj.v501i2.484
Issue
Vol. 501 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Thái Hòa, N. . (2021). TREATMENT RESULTS OF ADVANCED NON SMALL-CELL LUNG CANCER HARBOURING UNCOMMON EGFR MUTATIONS BY FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS. Vietnam Medical Journal, 501(2). https://doi.org/10.51298/vmj.v501i2.484

TREATMENT RESULTS OF ADVANCED NON SMALL-CELL LUNG CANCER HARBOURING UNCOMMON EGFR MUTATIONS BY FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS

Nguyễn Thị Thái Hòa

Main Article Content

Abstract

Rare mutations and double mutations account for less than 10% of lung cancers with EGFR mutations, often with a worse response to 1st generation TKIs than common mutations. Objective: To review some pathological features of advanced non-small cell lung cancer with rare EGFR mutation and to evaluate the response rate of this group of patients to 1st and 2nd generation TKIs. Subjects and methods: Retrospective description of 29 patients with stage IV non-small cell lung cancer with rare or double EGFR mutation Results: The rare mutation sites in the study were: G719X mutation, S768I mutation, L861Q mutation. Double mutations 7/29 patients (24%). The response rate and disease control with 1st generation TKIs was 41.7% and 66.7%; with 2nd generation TKIs 82.3% and 88.2%. Conclusion: 1st and 2nd generation TKIs are effective in rare and double EGFR mutations, and 2nd generation TKIs have a higher rate of disease response and control than 1st generation TKIs

Article Details

Keywords

Non-small-cell lung cancer, EGFR mutations, Tyrosine Kinase Inhibitors

References

1. Anh Thu Huynh Dang, et al (2020). “Actionable Mutation Profles of non-Small cell Lung cancer patients from Vietnamese population”, Scientific Reports, 10:2707 https:// doi.org/ 10.1038/s41598-020-59744-3 5
2. T. S. Mok, Y. L. Wu, S. Thongprasert et al (2009). “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma”. N Engl J Med, 361 (10), 947-957.
3. J. Y. Wu, C. J. Yu, Y. C. Chang et al (2011). “Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer”. Clin Cancer Res, 17 (11), 3812-3821.
4. J. C. Yang, M. Schuler, S. Popat et al (2020). “Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases”. J Thorac Oncol, 15 (5), 803-815.
5. James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater (2015). “Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6”. Lancet Oncology, VOLUME 16, ISSUE 7, P830-838, JULY 01, 2015.
6. Shen YC, Guan –Chin Tseng, Chih – Jeh Tu et al (2017). “Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations”. Lung Cancer, 2017Aug;110:56-62.
7. Barbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et all (2016), Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations, Journal of Thoracic Oncology, Vol. 11 No. 4: 545-555.